Leukemia & Lymphoma Society

Business & Community Leaders Join The Leukemia & Lymphoma Society's 2024 Visionaries Of The Year Annual Philanthropic Competition To Champion A World Without Blood Cancer

Retrieved on: 
Tuesday, March 5, 2024

Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.

Key Points: 
  • Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.
  • Participants of this have 10 weeks to raise funds that will directly support LLS's life-changing work.
  • LLS recognizes these inspiring individuals as "Visionaries," who are dedicated volunteers fundraising and creating awareness about blood cancer in their communities.
  • "Together, we will find cures and improve the quality of life for all those affected and ultimately create a world without blood cancer."

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

Retrieved on: 
Thursday, February 15, 2024

PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Key Points: 
  • PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.
  • Dusty Majumdar, PhD, CEO of PredxBio
    "We are thrilled and privileged to announce the appointment of Dr. Marks as the Chairman of PredxBio's Board of Directors," expressed Dusty Majumdar, PhD, CEO of PredxBio.
  • "I am honored to serve as Chairman of the Board of Directors at PredxBio," commented Dr. Marks.
  • Supported by over 20 peer-reviewed publications, 4000+ citations, and numerous patents, PredxBio contributes significantly to improving cancer care.

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®

Retrieved on: 
Tuesday, January 30, 2024

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
  • "We are honored by the support and recognition of LLS's Therapy Acceleration Program.
  • LLS's strategic investment in Rgenta continues to bolster our confidence in the potential of our pipeline of oral, small-molecule RNA-targeting medicines," commented Simon Xi, Ph.D., CEO of Rgenta.
  • "We look forward to tapping into the extensive clinical expertise and resources from LLS to accelerate the development of our RNA-targeting MYB inhibitor molecules."

Special Needs Network Welcomes Nicole Ring as Director of New Department, Unveils Expansion in Valencia and Bakersfield

Retrieved on: 
Tuesday, January 23, 2024

Los Angeles, California, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Special Needs Network is thrilled to announce the appointment of Nicole Ring as the Director of the newly established Department of Development and Special Initiatives.

Key Points: 
  • Los Angeles, California, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Special Needs Network is thrilled to announce the appointment of Nicole Ring as the Director of the newly established Department of Development and Special Initiatives.
  • "We are excited to have Nicole Ring join our team and lead the new Department of Development and Special Initiatives," said Special Needs Network Founder and President Areva Martin.
  • The opening of the new office in Valencia and the expansion of services in Bakersfield represent a significant step forward in the Special Needs Network's strategic growth.
  • Special Needs Network, Inc. is a nonprofit grassroots 501(c)(3) organization responding to the crisis of autism and other developmental disabilities in underserved communities.

City of Hope Children’s Cancer Center, Children’s Oncology Group conduct largest clinical trial seeking to prevent heart failure among childhood cancer survivors

Retrieved on: 
Tuesday, January 9, 2024

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children’s Oncology Group (COG) , have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

Key Points: 
  • Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children’s Oncology Group (COG) , have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.
  • View the full release here: https://www.businesswire.com/news/home/20240109428042/en/
    Physicians at City of Hope Children's Cancer Center, in cooperation with the Children’s Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.
  • Unfortunately, after the onset of heart function decline, the downward cascade is irreversible, highlighting an urgent need for early prevention strategies.
  • “The growing number of childhood cancer survivors makes the development of early interventions imperative.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on: 
Friday, December 8, 2023

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points: 
  • “We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
  • “Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
  • PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
  • Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Retrieved on: 
Tuesday, November 14, 2023

PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round.
  • The funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.
  • The additional capital will support Vittoria’s clinical development initiatives and advance its next-generation cell therapies that strengthen efficacy, improve safety, and broaden therapeutic applicability for patients with cancer and autoimmune diseases.
  • By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies.

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs

Retrieved on: 
Tuesday, December 5, 2023

RYE BROOK, N.Y., Dec. 5, 2023 /PRNewswire/ -- At the 65th Annual American Society of Hematology (ASH) Annual Meeting (December 9-12 in San Diego), The Leukemia & Lymphoma Society (LLS) will present new research findings, and proudly support more than 200 LLS-funded researchers, as well as 15 current and former LLS Therapy Acceleration Program® (TAP) partners, who will share their study results.

Key Points: 
  • The next big advances are in the works," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer.
  • LLS funding has helped advance more than 70% of blood cancer treatment options approved by the U.S. Food and Drug Administration in the last six years.
  • LLS research selected for presentation at ASH includes:
    New data from two master clinical trials convened and led by LLS: the Pediatric Acute Leukemia Master Clinical Trial ( PedAL ) and the Beat AML® Master Clinical Trial .
  • The Beat AML Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer, uses advanced technology to provide genomic analysis to match patients to precision treatment within seven days.

National Film Festival Debuts Documentary About First-of-Its-Kind Blood Cancer Master Clinical Trial

Retrieved on: 
Wednesday, November 15, 2023

RYE BROOK, N.Y., Nov. 15, 2023 /PRNewswire/ -- The story of a clinical trial that is unlocking a new, personalized treatment approach with the power to save the lives of thousands of people living with an aggressive and deadly form of leukemia was screened at the American Public Health Association Film Festival this week. 

Key Points: 
  • "Coloring Outside the Lines" follows the story of four patients with acute myeloid leukemia (AML), their medical teams, and the scientists who created a first-of-its kind blood cancer master clinical trial that is transforming how this disease is treated.
  • The film captures the stories of Dorila, Jerry, Martha and Susan, who enrolled in the Beat AML® Master Clinical Trial.
  • "Leading scientists saw a major unmet need in blood cancer treatment and dove in to create something the medical world had never seen before: the first collaborative precision medicine master clinical trial for blood cancer," said E. Anders (Andy) Kolb, M.D., president and CEO of The Leukemia & Lymphoma Society (LLS).
  • In addition to the stories of individuals enrolled in the trial, the documentary also features the doctors who treated them and the scientific leaders and partners behind the trial.

Unleashed Brands Honors Franchisees at Annual Conference

Retrieved on: 
Thursday, November 9, 2023

DALLAS, Nov. 9, 2023 /PRNewswire/ -- Unleashed Brands, the world's first youth enrichment franchise platform, recently recognized the achievements of more than two dozen franchisees across category-leading brands Urban Air Adventure Park, Snapology, The Little Gym, XP League, Class 101 and Premier Martial Arts at the company's annual franchisee conference in Hollywood, CA.

Key Points: 
  • DALLAS, Nov. 9, 2023 /PRNewswire/ -- Unleashed Brands , the world's first youth enrichment franchise platform, recently recognized the achievements of more than two dozen franchisees across category-leading brands Urban Air Adventure Park, Snapology , The Little Gym , XP League , Class 101 and Premier Martial Arts at the company's annual franchisee conference in Hollywood, CA.
  • The event connected franchisees from across the brands with more than 1,000 people in attendance.
  • The conference was centered on team building and workshops aimed to inspire and help franchisees grow their businesses.
  • The conference also marked the official debut of the Unleashed Brands Foundation , the charitable arm of Unleashed Brands committed to empowering at-risk youth and providing resources needed to successfully transition to adulthood through education, financial support and in-person volunteerism efforts.